Johnson & Johnson’s Spravato (esketamine) For Treatment-Resistant Depression
The U.S. Food & Drug Administration Tuesday approved Johnson & Johnson’s ketamine-derived nasal spray Spravato for treatment-resistant depression. The approval means ketamine—an... Read More
FDA has granted Johnson & Johnson’s esketamine Breakthrough Therapy Designation (BTD)
FDA has granted Johnson & Johnson’s esketamine, an experimental antidepressant treatment Breakthrough Therapy Designation (BTD). The designation was granted for major depressive... Read More